Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: silicon warrior who wrote (679)	7/31/1998 12:40:00 PM
From: Boriana I.	Respond to of 756

Guys I don't want to disappoint anybody but why would they beat estimates? Where are all these earnings going to come from - a slight revision sure but 300%? Where from? However I do hope you are right and will be thankful for any comments before close. P.S. I just saw that you are right - they have made o.o3 but thenwhy is there no substantial movement in the price?

To: silicon warrior who wrote (679)	7/31/1998 2:27:00 PM
From: George Mc Geary	Read Replies (1) \| Respond to of 756

Friday July 31, 10:24 am Eastern Time Company Press Release SOURCE: IVX BioScience, Inc. IVX BioScience Announces 1998 Second Quarter Results MIAMI, July 31 /PRNewswire/ -- IVAX Corporation, doing business as IVX BioScience, Inc. (Amex: IVX - news) today reported its financial results for the quarter ended June 30, 1998. Net income per share for the 1998 second quarter was $.03, compared to a net loss per share of $.39 in the 1997 second quarter. Net income for the 1998 second quarter was $3.3 million, compared to a net loss of $47.5 million in the 1997 second quarter. Net revenues for the 1998 second quarter were $158.7 million, compared to $173.8 million in the 1997 second quarter. Gross profit for the 1998 second quarter was $60.2 million, compared to $45.7 million in the 1997 second quarter. For the first six months of 1998 the company was approximately breakeven on a per share basis, compared to net loss per share of $.46 for the same period in 1997. Net loss for the first half of 1998 was $.6 million, compared to net loss of $55.5 million for the first half of 1997. Net revenues for the first six months of 1998 were $307.7 million, compared to $340.7 million for the same period in 1997. Gross profit for the 1998 first half was $110.0 million, compared to $94.6 million in the first half of 1997. The 1997 second quarter results include a one-time $20.5 million restructuring charge. ''I am very pleased that the restructuring we implemented to reduce costs and improve efficiencies is being manifested in positive earnings for IVX BioScience. I am particularly gratified by not only a second consecutive quarter of profits from operations at Zenith Goldline, our U.S. generic drug subsidiary, but also the growth in profits from the first to the second quarter. Our other major business units, located in the United Kingdom and the Czech Republic, were profitable as well,'' said Phillip Frost, IVX BioScience Chairman and Chief Executive Officer. ''Separately, we and our investment bankers continue to move forward with the previously announced strategic evaluation of our various businesses.'' IVX BioScience, Inc., headquartered in Miami, Florida, is a holding company with core subsidiaries engaged in the research, development, manufacture and marketing of generic and branded pharmaceuticals. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, and certain economic, competitive, governmental, technological and other factors discussed in IVAX's filings with the Securities and Exchange Commission.